AN2 Therapeutics (ANTX) Total Current Liabilities (2021 - 2026)

AN2 Therapeutics (ANTX) has 6 years of Total Current Liabilities data on file, last reported at $5.6 million in Q1 2026.

• On a quarterly basis, Total Current Liabilities changed N/A year-over-year to $5.6 million in Q1 2026; TTM through Mar 2026 was $5.6 million, a N/A change from a year earlier, with the FY2025 full-year figure at $8.7 million, down 14.83% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $5.6 million, down from $8.7 million in the prior quarter.
• Over the last five years, Total Current Liabilities for ANTX reached as high as $14.8 million in Q3 2023 and fell as low as $4.1 million in Q2 2022.
• Historically, Total Current Liabilities has averaged $8.7 million across 5 years, with a median of $8.6 million in 2023.
• Across the five-year window, Total Current Liabilities jumped 234.81% in 2023 and slumped 32.5% in 2024, its largest moves.
• Year by year, Total Current Liabilities stood at $7.2 million in 2022, then soared by 95.42% to $14.0 million in 2023, then declined by 27.1% to $10.2 million in 2024, then decreased by 14.83% to $8.7 million in 2025, then plunged by 36.22% to $5.6 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $5.6 million in Q1 2026, $8.7 million in Q4 2025, and $10.2 million in Q4 2024.